Abstract Details

Title Role of Cytokines in Acute Ischemic Stroke Patients: Preliminary Analysis of a Prospective Database

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P1 - Poster Session 1 (12:00 PM-1:00 PM)

Poster/Presentation
Number 4-018

Objective

To find the role of various cytokines as blood biomarkers in Acute Ischemic Stroke patients

Background Acute ischemic stroke (AIS) is a leading cause of disability with alteplase as the only acute pharmacological treatment approved to date. Various modalities of management and diagnosis are being evaluated. The role of various cytokines is of particular interest. There is limited data on the role of various cytokines such as IL1, IL-6, IL-23, IL-37, MPO and MMP-9 in patients with acute ischemic stroke. This current study is a preliminary analysis of a large prospective study.

Design/Methods

This prospective study was approved by the institutional IRB. Patients presenting to an academic tertiary hospital with the diagnosis of AIS were included. All the patients with prior history of stroke, autoimmune diseases, and neurodegenerative diseases were excluded. Patients were categorized into two grouped: AIS group and Control group. The trends in plasma levels of above mentioned cytokines were measured by enzyme-linked immunosorbent assay (ELISA).

Results

This is a preliminary data from a subset of the anticipated larger cohort. Fifty five consenting patients (45 cases and 5 controls) were analyzed in the first phase. There were 23 females in AIS and 6 females in control groups. Caucasian and Hispanics were primarily the predominant ethnicity in both groups. The study showed positive trend of Plasma IL-33, IL-37, and MPO levels between the two groups but the difference was not statistically significant.

Conclusions

This preliminary data showed a trend of elevated plasma IL-33, IL-37 and MPO levels in AIS patients as compared to control subjects. These are early observations from an anticipated a large-scale prospective study "CRISP" trial registered with the ClinicalTrials.gov (Identifier: NCT03297827) to determine the role of various cytokines, in modulating post-stroke inflammation.

Authors/Disclosures
Sajid Suriya, MD PRESENTER	Dr. Suriya has nothing to disclose.
Mudassir Farooqui, MD	Dr. Farooqui has nothing to disclose.
Asad Ikram, MD, MBBS	Dr. Ikram has nothing to disclose.
Dania Qaryouti, MD (University of New Mexico)	Dr. Qaryouti has nothing to disclose.
Syed A. Quadri, MD (Massachusetts General Hospital, Harvard Medical School)	Dr. Quadri has nothing to disclose.
Santiago Ortega Gutierrez, MD (University of Iowa)	Dr. Ortega Gutierrez has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for stryker. Dr. Ortega Gutierrez has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for medtronic. Dr. Ortega Gutierrez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. The institution of Dr. Ortega Gutierrez has received research support from stryker. The institution of Dr. Ortega Gutierrez has received research support from Medtronic. The institution of Dr. Ortega Gutierrez has received research support from Methinks. The institution of Dr. Ortega Gutierrez has received research support from NIH. The institution of Dr. Ortega Gutierrez has received research support from PCORI.
	No disclosure on file
Atif Zafar, MD (St. Michael's Hospital (University of Toronto))	Dr. Zafar has nothing to disclose.